---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-022375"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T07:34:01.963939+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed prices $750M common stock offering at $96/share for brensocatib R&D and commercialization

## Summary
- Priced 7,812,500 shares at $96.00; net proceeds ~$716.3M after underwriting discounts.
- Underwriters granted 30-day option for up to 1,171,875 additional shares (~$112.5M).
- Proceeds to fund brensocatib R&D, pre-commercial/commercial, ARIKAYCE, TPIP, INS1201, and general corporate.
- Offering expected to close June 13, 2025; joint book-runners: Goldman Sachs, Leerink, BofA, Jefferies, J.P. Morgan.

## SEC filing metadata
- accession: 0001140361-25-022375
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/0001140361-25-022375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/ny20050461x3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-022375
- JSON: https://secwatch.observer/filing/0001140361-25-022375.json
- Plain text: https://secwatch.observer/filing/0001140361-25-022375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.